

Christopher Nevala-Plagemann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9119432/publications.pdf>

Version: 2024-02-01

10
papers

299
citations

1937685

4
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

600
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment Trends and Clinical Outcomes of Left-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer in the United States. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 268-275.	4.9	3
2	Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 144-150.	4.9	4
3	Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2021, 50, 796-802.	1.1	1
4	Emerging Treatment Strategies in Pancreatic Cancer. <i>Pancreas</i> , 2021, 50, 773-787.	1.1	3
5	Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110458.	3.2	7
6	Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 478-482.	4.9	21
7	From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 108-123.	27.6	244
8	Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. <i>JCO Precision Oncology</i> , 2020, 4, 780-784.	3.0	2
9	Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab. <i>ESMO Open</i> , 2019, 4, e000539.	4.5	3
10	Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. <i>ESMO Open</i> , 2018, 3, e000386.	4.5	11